Eliminating the buprenorphine DEA X waiver is critical to promote health equity

Expanding access to nurse-managed medication for opioid use disorder (2021) provides an assessment of challenges that advanced practices nurses (APRNs) experience in providing buprenorphine, a partial opioid agonist, and life-saving treatment for Opioid Use Disorder (OUD). While Cos  et al. (2021) put forward recommendations to facilitate nursing contributions, eliminating the required DEA X waiver to prescribe buprenorphine was only briefly mentioned.

Source: Nursing Outlook - December 8, 2021 Category: Nursing Authors: Katie Fitzgerald Jones, Monica O'Reilly-Jacob, Mathew Tierney Source Type: research